The content on this site is intended for healthcare professionals only
At a press conference during the ASCO 2012 Annual Meeting in Chicage, June 1st - June 4th, Dr Hope Rugo presents results from a phase III randomised trial that found weekly administration of either of two newer and significantly more costly agents, nanoparticle albumin bound (“nab”) paclitaxel (Abraxane) and ixabepilone (Ixempra), was not superior to standard weekly dosing of paclitaxel as first-line therapy for locally advanced or metastatic breast cancer.
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant
Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer
EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer
Comment: EBCC 2024 highlights
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours
Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy
